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The ability of the immune system to treat established
tumors is very well recognized. Immunotherapeutic
approaches such as Adoptive T cell therapy and anti-
CTLA-4 antibody treatment can result in long-term
responses in some patients with metastatic melanoma.
However, the majority of patients do not respond. A
thorough understanding of the mechanisms by which
tumors resist T cell mediated killing is thus crucial for
the design of appropriate combinations of immune- and
targeted therapies and for defining potential biomarkers
that can distinguish responders, with the ultimate goal of
achieving durable disease free regressions in many more
patients. To approach these two different but overlapping
goals, we adapted an in vitro assay of T cell mediated
cytotoxicity for high throughput screening. In this assay,
cytotoxicity is measured by intracellular staining of active
Caspase-3 in tumor cells followed by flow cytometry in
96 well plates. A number of human melanoma cell lines
and their autologous TILs (Tumor infiltrating lympho-
cytes) were tested and candidate pairs were chosen for a
screen of 850 compounds to identify drugs that are
synergistic with T cell mediated killing and hence can be
used in combinations with immunotherapies. In this
study, we are focusing on a class of drugs that inhibit
Heat shock protein 90 (Hsp90). Briefly, the tumor line is
treated with the drugs for 24 hours, followed by addition
of autologous T cells that kill these treated tumor cells. A
combo score for apoptosis in tumor cells is calculated for
each drug. A higher score indicates that the treatment of
the tumor with the drug renders it more sensitive to
T cell mediated killing. We show that three Hsp90 inhibi-
tors, 17 DMAG, 17AAG and BIIB021, show a high
combo score with T cell mediated cytotoxicity. The
synergy of this drug treatment with T cell mediated cyto-
toxicity suggests that this category of compounds maybe
beneficial in combination therapies. We are currently
testing 17AAG with immunotherapies such as anti
CTLA-4, anti PDL1 and anti OX40 in different tumor
models in mice. Experiments are underway to understand
the changes in signaling pathways (by RPPA) and gene
expression (by microarray) on treatment of different
tumor lines with 17AAG to mechanistically understand
the role of Hsp90 in development of resistance to direct
T cell mediated cytotoxicity. This screen will serve as a
pipeline for combinations that would lead to new clinical
trials as well as identify novel mechanisms of cancer
immune resistance.
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